NEW YORK, Feb. 05, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Imprivata, Inc. (“Imprivata” or the “Company”) (NYSE:IMPR) in the United States District Court of Massachusetts on behalf of a class consisting of all persons or entities who purchased Imprivata securities between July 30, 2015 and November 2, 2015, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or omitted material information concerning demand for the Company’s IT security offerings and its sales trends, which inflated the price of Imprivata stock. The Complaint further alleges that certain Company executives and insiders took advantage of the inflation by selling more than $72 million worth of personally-held Imprivata stock during this time period.
If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
FDA Approves Mitapivat for Anemia in Thalassemia Patients
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 



